Artivion (AORT) Scheduled to Post Earnings on Thursday

Artivion (NYSE:AORT) is scheduled to post its quarterly earnings results after the market closes on Thursday, November 7th. Analysts expect Artivion to post earnings of $0.03 per share for the quarter. Artivion has set its FY 2024 guidance at EPS.Parties that are interested in registering for the company’s conference call can do so using this link.

Artivion (NYSE:AORT) last posted its quarterly earnings data on Thursday, August 8th. The company reported $0.07 EPS for the quarter, beating the consensus estimate of $0.03 by $0.04. Artivion had a positive return on equity of 3.81% and a negative net margin of 2.22%. The firm had revenue of $98.02 million during the quarter, compared to the consensus estimate of $97.70 million. On average, analysts expect Artivion to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Artivion Stock Up 0.5 %

AORT traded up $0.14 on Tuesday, hitting $27.60. 17,882 shares of the company’s stock were exchanged, compared to its average volume of 220,778. Artivion has a fifty-two week low of $13.18 and a fifty-two week high of $29.24. The firm has a 50-day moving average price of $26.03 and a 200-day moving average price of $24.95. The company has a current ratio of 5.63, a quick ratio of 4.04 and a debt-to-equity ratio of 1.07.

Insider Activity at Artivion

In other Artivion news, VP Matthew A. Getz sold 9,420 shares of the firm’s stock in a transaction on Friday, August 16th. The stock was sold at an average price of $25.31, for a total transaction of $238,420.20. Following the completion of the sale, the vice president now owns 34,116 shares of the company’s stock, valued at $863,475.96. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, SVP Jean F. Holloway sold 3,167 shares of the company’s stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $26.55, for a total value of $84,083.85. Following the transaction, the senior vice president now directly owns 161,932 shares in the company, valued at approximately $4,299,294.60. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, VP Matthew A. Getz sold 9,420 shares of the stock in a transaction that occurred on Friday, August 16th. The stock was sold at an average price of $25.31, for a total transaction of $238,420.20. Following the transaction, the vice president now directly owns 34,116 shares of the company’s stock, valued at $863,475.96. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 37,109 shares of company stock worth $951,935. Insiders own 8.10% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the stock. Oppenheimer upped their price objective on shares of Artivion from $25.00 to $30.00 and gave the company an “outperform” rating in a research note on Friday, August 9th. Stifel Nicolaus upped their price target on Artivion from $28.00 to $30.00 and gave the company a “buy” rating in a research report on Friday, September 13th. Needham & Company LLC reiterated a “buy” rating and set a $30.00 price objective on shares of Artivion in a research report on Friday, September 27th. Finally, JMP Securities started coverage on Artivion in a report on Wednesday, October 23rd. They issued an “outperform” rating and a $33.00 target price for the company. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $30.60.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.